Fundraising FoxHBM Healthcare Investments
Crossover fundZug · Growth–Late Stage · 8 people tracked
Find your way into HBM Healthcare Investments
35 people in our graph share verified history with the HBM Healthcare Investments team — schools, employers, funds. One of them is your warm intro.
Investment thesis
HBM Healthcare Investments invests globally in the healthcare sector, building a diversified portfolio spanning private and publicly listed companies. The firm views healthcare as an attractive, fast-growing investment universe driven by demographic trends such as population growth and aging, ongoing medical progress and innovation, rising prosperity in emerging markets, and improved access to medical products and services. Persistent demand for new therapies across a growing range of diseases and continuous innovation in products, services and business models underpin the strategy. As a listed company (HBMN), it has delivered attractive NAV and share price performance alongside a distribution yield of roughly 3 to 5 percent per year.
Source: firm website, verified Sep 27, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 49 of 64 portfolio companiesBiotech ×39Healthtech ×36Medical Devices ×19AI & Machine Learning ×8Digital Health ×8Deep Tech ×6E-commerce ×3B2B Marketplaces ×1
HQs:United States×34Germany×2Switzerland×1China×1India×1Italy×1
Investments · 64 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12022 · 32021 · 22020 · 22019 · 12018 · 12017 · 52016 · 22015 · 120 dated
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalHBM PartnersNextech InvestOrbiMedSamsara BioCapitalSR One Capital Management+3 more
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM PartnersvenBio PartnersLogos+1 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+12 more
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM PartnersParagon Biosciences LLCPivotal Life SciencesValor Equity PartnersvenBio Partners+3 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Co-investorsAndera PartnersHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios CapitalAdams Street Partners+3 more
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalHBM PartnersNew Enterprise Associates (NEA)Versant VenturesAmzak HealthAvoro Capital Advisors+2 more
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture Partners+3 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Partners+4 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Lumira VenturesNextech InvestWUTIF CapitalAmplitude Venture Capital
1000Farmacie is an Italian online pharmacy and parapharmacy marketplace that aggregates products from over 60 partner pharmacies and other sellers, offering over 100,000 products for health and wellness including pharmaceuticals, medical devices, veterinary medicines, homeopathic and ayurvedic products, with home delivery across Italy.
B2B MarketplacesE-commerceHealthtechItaly, IT
Nicolo Petrone(Founder)inAlberto Marchetti(Founder)in
Co-investorsClub degli InvestitoriHBM PartnersItalian Angels for GrowthLIFTTP101 Ventures
This is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth.
Digital HealthE-commerceHealthtechIndia, IN
Co-investorsHBM PartnersKae CapitalLeo Capital VenturesPeak XV PartnersSpring Marketing CapitalVenturEast+3 more
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication.
BiotechHealthtechMedical DevicesHennigsdorf, DE
Gerald Moeller(Co-founder and former CEO of AdrenoMed; Supervisory Board member)inRichard Jones(Chief Executive Officer (CEO))inDavid Germonpré(Chief Financial Officer (CFO))in
Co-investorsBrandenburg KapitalCatalyze CapitalHBM PartnersVU Venture Partners
Amphora provides logistics services aimed at supporting business growth and operational efficiency.
E-commerceLogistics & Supply ChainSaaS
Joan Tresserras(Founder)inAdrià Cortés(Founder)in
Co-investorsBStartupLongitude CapitalBaird CapitalF-Prime Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGV (Google Ventures)HBM Partners+6 more
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent Capital+3 more
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBioGeneration VenturesMPM BioImpactPMVSeventure Partners
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
%20copy.jpg)
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM PartnersNextech InvestOUP (Osage University Partners)+3 more
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM PartnersHongShan Capital GroupLAV+4 more
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)OrbiMed
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersFrazier Healthcare PartnersNovo HoldingsT. Rowe Price+2 more
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsAvego BioScience CapitalFuture Planet CapitalHBM PartnersRA CapitalBrightEdgeForbion+1 more
connectRN operates a mobile app marketplace that matches nurses and clinicians with open shifts at healthcare facilities such as hospitals, home health, and hospice across the US.
Future of WorkHealthtechHR TechMarketplacesWaltham, US
Ted Jeanloz(Executive Officer)in
BoardMichael Jasulavic(Director)John Pappajohn(Director)Geoffrey Harris(Director)Idriz Limaj(Director)
Co-investorsData Point CapitalHBM Partners
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesJanus Henderson InvestorsMedicxi
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalHBM PartnersMission Bay CapitalMission BiocapitalOlive Tree Capital+4 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM PartnersKhosla VenturesLifeSci Venture Partners+13 more
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM PartnersOrbiMedRA CapitalWestlake Village BioPartnersKleiner PerkinsNVIDIA
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture CapitalSR One Capital Management+3 more
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Co-founder and Chief Technical Officer)in
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesHBM PartnersIPD Capital+6 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity Investments+5 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersPivotal Life SciencesRA CapitalSamsara BioCapital+3 more
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)in
Co-investors5AM VenturesDCVC (Data Collective)HBM PartnersKhosla VenturesLightspeed Venture PartnersSeventure Partners+1 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsREDMILEVersant VenturesHBM PartnersBAM ElevateFranklin TempletonInvus+5 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Executive Officer, Director)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsDroia VenturesHBM PartnersHealthCapMitsui Global InvestmentVenrockVenrock Associates
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig C. Chambliss(Executive Officer, Director)inCraig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsHBM PartnersLYZZ CapitalOrbiMed
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURES+2 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM PartnersLAVLilly Asia VenturesRA CapitalSamsara BioCapital+2 more
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM PartnersBiotechnology Value FundBlackRockForbionNovo Holdings+1 more
Shape Memory Medical develops embolization and occlusion medical devices built on a bioabsorbable shape memory ("smart") polymer that expands to conform to vascular anatomy.
HealthtechSan Jose, US
Duncan Maitland(Director)inMichael Henson(Executive Officer, Director)inEdward F. Ruppel, Jr(Executive Officer, Director)Carolyn M. Bruguera(Executive Officer)James Y Lancaster(Executive Officer, Director)in
BoardThom Rasche(Director)
Co-investorsEmergent Medical Partners, LLPHBM PartnersEarlybird Venture CapitalTaiwania Capital
SphingoTec develops proprietary biomarkers for critical care diagnostics, addressing acute kidney injury, sepsis, and acute heart failure through partnerships with in vitro diagnostics companies and pharmaceutical firms.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHennigsdorf, DE
Deborah Bergmann(Chief Executive Officer)in
Co-investorsBrandenburg KapitalHBM Partners
Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsBain Capital Life SciencesHBM PartnersMérieux Equity PartnersSK Capital Partners
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields.
AI & Machine LearningBiotechHealthtech
David Berry(Founder)in
Co-investorsAtinum Investment Co. Ltd.BioGenerator VenturesFlagship PioneeringHBM PartnersKoch Disruptive Technologies
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADARxAmphora MedicalBaseHealthC-Ray TherapeuticsCathay BiotechComplexaCorvidia TherapeuticsCORXEL PharmaceuticalsCrystlaysCure Everlife HoldingsCurevoFangzhou / JiankeFarmalatamIgnis TherapeuticsNuance BiotechOnesourceRiver RenalSpringWorks TherapeuticsSwixx HealthcareSymbiomix TherapeuticsVascular DynamicsVisen Pharma
Exits · 15
11 IPOs · 4 acquisitions · showing 13AlumisNASDAQ: ALMSAlx OncologyNASDAQ: ALXOFreenomeNASDAQ: FRNMHarmony BiosciencesNASDAQ: HRMYMineralys TherapeuticsNASDAQ: MLYSMonte Rosa TherapeuticsNASDAQ: GLUENateraNASDAQ: NTRAParabilis MedicinesNASDAQ: PBLSUpstream BioNASDAQ: UPBZymeworksNASDAQ: ZYMEAmphora Medicalacq. by HologicBluejaytxacq. by Mirum PharmaceuticalsCurevoacq. by Eli Lilly and Company
Frequently asked questions
- How many investments has HBM Healthcare Investments made?
- HBM Healthcare Investments has 64 tracked investments, 15 of which have exited, including 2 dated in the last 24 months.
- What stage does HBM Healthcare Investments invest at?
- HBM Healthcare Investments invests at the Growth, Late Stage stages.
- What sectors does HBM Healthcare Investments focus on?
- HBM Healthcare Investments focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is HBM Healthcare Investments located?
- HBM Healthcare Investments is headquartered in Zug, CH.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
ARTIS Ventures is a venture capital firm investing in breakthrough companies at the convergence of technology and biology, with a focus on healthcare and life sciences ('TechBio'). It backs founders across biotech, therapeutics, digital health, and frontier technologies.